AK-119 is under clinical development by Akaal Pharma and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase I drugs for Multiple Sclerosis have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AK-119’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AK-119 overview
AK-119 is under development for the treatment of multiple sclerosis and neuropathic pain, atopic dermatitis associated pruritis. The drug candidate is administered as an oral capsule. It acts by targeting sphingosine-1-phosphate (S1P) receptor.
Akaal Pharma overview
Akaal Pharma is a clinical-stage drug discovery and development company that focuses on developing treatment of pruritus and inflammatory skin diseases as topical drugs. The company’s oral drug development is focused on neuropathy, pain and autoimmune skin diseases. Akaal Pharma’s drug pipeline contains innovative small molecule drugs for the treatment of pruritus, neuropathic pain, inflammatory skin diseases and autoimmune indications. It works in partnership with pharmaceutical and biotechnology companies. Akaal Pharma is headquartered in Melbourne, Victoria, Australia.
For a complete picture of AK-119’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
